Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
03:54am, Tuesday, 16'th Dec 2025
Shares of AstraZeneca PLC (NASDAQ: AZN - Get Free Report) have been given an average rating of "Moderate Buy" by the nine ratings firms that are covering the stock, MarketBeat reports. One analyst has
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
07:16pm, Monday, 15'th Dec 2025
Astrazeneca (AZN) closed the most recent trading day at $91.56, moving +1.93% from the previous trading session.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of
Geneos Wealth Management Inc. Grows Stock Holdings in AstraZeneca PLC $AZN
04:09am, Monday, 15'th Dec 2025
Geneos Wealth Management Inc. boosted its holdings in AstraZeneca PLC (NASDAQ: AZN) by 329.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Com
AstraZeneca (LON:AZN) Share Price Crosses Above 200-Day Moving Average – Should You Sell?
04:02am, Friday, 12'th Dec 2025
AstraZeneca PLC (LON: AZN - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of £117.76 and traded as high as £136.
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
10:26am, Wednesday, 10'th Dec 2025
AstraZeneca (AZN) offers a rare, secular growth profile in biopharma, underpinned by a diversified commercial asset base and layered patent expirations. AZN faces a minor patent cliff, with most key p
Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO
05:34pm, Tuesday, 09'th Dec 2025
Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh
Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab 47% of patients exhibited complete responses (CR), with an overall response rate of 80% F
Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailing
07:33am, Monday, 08'th Dec 2025
JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in glo
Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement
04:00pm, Thursday, 04'th Dec 2025
SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentf
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
07:00am, Thursday, 04'th Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH)
3 Potential Mid-Cap Biotech Buyout Targets In 2026
06:22pm, Wednesday, 03'rd Dec 2025
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
11:05am, Wednesday, 03'rd Dec 2025
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 03'rd Dec 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
09:18am, Tuesday, 02'nd Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatmen
